Release pattern of three new polymers in Ketoprofen controlled-release tablets
|
|
- Lorin Bennett
- 5 years ago
- Views:
Transcription
1 African Journal of Pharmacy and Pharmacology Vol. 6(9), pp , 8 March, 2012 Available online at DOI: /AJPP ISSN Academic Journals Full Length Research Paper Release pattern of three new polymers in Ketoprofen controlled-release tablets Syed Umer Jan 1 *, Gul Majid Khan 2, Haroon Khan 2, Asim-ur-Rehman 2, Kamran Ahmad Khan 2, Shefaat Ullah Shah 2, Kifayat Ullah Shah 2, Amir Badshah 3 and Izhar Hussain 4 1 Department of Pharmacy, University of Balochistan, Quetta, Pakistan. 2 Faculty of Pharmacy, Gomal University, D. I. Khan, Pakistan. 3 Department of Pharmacy, University of Peshawar, Pakistan. 4 Department of Pharmacy, COMSATS Institute of Information Technology, Abbottabad, Pakistan. Accepted 24 February, 2012 The objective of the study was to formulate and evaluate sustained release polymeric tablets of ketoprofen for the release rate, release patterns and the mechanism involved in the release process of the drug. Formulations with three different types of newly synthesized polymers and one grade of ethyl cellulose ether derivatives (FP100 premium) in several drug-to-polymer ratios (D:P ratio 10:1, 10:2 and 10:3) were compressed into tablets using the direct compression method. They were examined for their physical properties and appearance. Tablets dimensional tests (thickness, diameter) and Q.C tests (hardness, friability, disintegration) were performed according to the USP methods. For in vitro drug release studies of Ketoprofen controlled release (CR) tablets, the USP Method-1 (Rotating Basket Method) was used with Pharma test dissolution apparatus (D Hainburg, Germany). The medium used for dissolution was phosphate buffer having a ph of 7.4 kept at constant temperature of 37±1 C. In order to analyze the drug release kinetics from each of the prepared matrices, five different mathematical models were applied to the release data including zero order kinetics, first order kinetics, Higuchi kinetics, Hixson Crowell kinetics and Korsmeyer Peppas equations were applied to the release data. The results obtained from different parameters showed that polymers: Polyglycolide, PGA-cocaprolactone, PGA-co-pentadecalactone and Ethocel FP100 premium can be used successfully in order to develop directly compressed prolonged release tablets of slightly soluble drugs such as ketoprofen. Particle size of polymer is a determining factor in controlling the release of ketoprofen from tablets. Ethocel standard FP100 polymers extend the release rates of drug more efficiently than the conventional granular form of the other three polymers. Further, the three new polymers and Ethocel FP100 could efficiently extend the release of the drugs as compared to the reference conventional formulation. Key words: Polymers, Ketoprofen, controlled-release preparations. INTRODUCTION Efforts have been made in drug delivery system, e.g. targeted drug delivery system in which the drug is active in targeted area of the body to which it is targeted and sustained release formulation in which the drug is released over a period of time in controlled manner and specific time interval from the product (Drug Delivery, *Corresponding author: suj55@yahoo.com. Tel: ). Ketoprofen is a drug belonging to the group of nonsteroidal anti-inflammatory drugs (NSAIDs). It is a propionic acid derivative and is used in the treatment of rheumatoid arthritis. Its chemical formula is given as 2- benzoyl-3-phenyl propionic acid (Liversidge, 1981). Like other NSAIDs, ketoprofen is used in clinics as an antiinflammatory and analgesic drug for the treatments of rheumatoid arthritis and osteoarthritis (Therapeutic Drug Volume, 1991). Ketoprofen has advantages over other NSAIDs because it has no or very little addictive potential and also has no effect on sedation and depression of
2 602 Afr. J. Pharm. Pharmacol. respiration (Green, 2001). NSAIDs including ketoprofen have poor tolerability profile having some adverse effects (Evans, 1996). Due to inhibition of COX-1, various side effects are produced; whereas, on the inhibition of COX-2, their therapeutic effects are developed (Villegas et al., 2004). Some common adverse effects are gastrointestinal tract complaints such as nausea, vomiting and epigastric discomfort. Certain nervous system disorders include headache, drowsiness and dizziness, and also lower gastro intestinal tract infection (Vavra, 1987). Certain studies were performed in mice, rats and dogs, etc, in which rats were found to exhibited gastrointestinal tract (GIT) and renal system toxicity (Kantor, 1986). Dogs were also found to be susceptible for ulceration and irritation of GIT but no carcinogenic effect was found in standard screening assays (Kantor, 1986). To overcome these adverse effects, it was thought to prepare controlled release matrix formulations of ketoprofen using three newly synthesized polymers along with one ethyl cellulose ether derivatives (Ethocel FP100 premium) for comparison. Ethocel standard FP premium is the new product; it exists in a very fine particle form, thus allowing the use of direct compression to incorporate into the controlled release matrix (Khan and Zhu, 2001a, Wahab et al., 2011). The new polymers, if made into fine particles will give more extended release which can be used as polymers of choice in CR formulations in future. We also studied other viscosity grades of polymer Ethocel, and data is already published, (Jan et al., 2011) and only one grade compared (FP 100) with the newly synthesized polymers. The objective of the study was to formulate and evaluate sustained release polymeric tablets of ketoprofen for the release rate, release patterns and the mechanism release rate, release patterns and the mechanism involved in the release process of the drug. METHODOLOGY Material and chemicals Monobasic potassium phosphate, NaOH, (Merck, Germany), ketoprofen, lactose, magnesium stearate (BDH Chemical Ltd, Pool England), polymers polyglycolic acid (PGA), PGA-co-caprolactone, PGA-co-pentadecalactone and Ethocel FP100 Premium, Pharma test dissolution apparatus (D-63512, Hainburg), UV-Visible spectrophotometer (UVIDEC-1601 Shimadzu, Japan), single punch tablet machine (Erweka AR 400, Germany), hardness tester (Erweka Apparatus TB24, Germany), friability tester (Erweka TA3R, Germany). Construction of standard calibration curve 20 mg of ketoprofen was taken in a 100 ml volumetric flask for the preparation of stock solutions in 100 ml phosphate buffer (ph 7.4). The drug was dissolved using ultra-sonifier. This stock solution was used for further dilutions. 50 ml of this stock solution was taken in a 100 ml volumetric flask and 50 ml of the buffer was added to increase the volume to 100 ml. The concentration of the drug in this first dilution was 0.1 mg/ml. Then from this dilution, 50 ml was taken and further diluted to 100 ml, where the buffer the drug concentration in solution was 0.5 mg/ml. Similarly 0.025, and mg/ml dilutions were prepared in the same way. These dilutions were then analyzed at 258 nm using UV visible spectrophotometer. Formulation development 200 mg tablet of ketoprofen containing 100 mg drug and three new types of polymers and Ethocel FP100 premium grade at drug to polymer ratio of 10:1, 10:2, and 10:3 were developed. Lectose was used as filler and 0.5% magnisium stearate was used as a lubricant. The formulations are given in Table 1. Preparation of tablets The drug and polymer were weighed and mixed using mortar and pestle, and then filler was added and mixed. All these ingredients were passed through 30 mesh sieve screen. Lubricant was added in the end, then again passed twice through the same sieve, and were directly compressed in tablets using single punch tablet machine (Erweka AR 400, Germany). Physical characterization of the tablets After the tablet preparation, the quality control tests were carried out for each formulation. These tests includes, hardness test performed for ten tablets according to USP method, using hardness tester (Erweka, Germany).The dimensional tests of the tablets were performed using Vernier caliper according to USP method. The friability test was carried out in a friabilator on 20 tablets from each formulation. Disintegration test was performed on six tablets from each formulation, using disintegration apparatus. All the physical tests performed were within established ranges. In vitro drug release study For dissolution study, Pharma test dissolution apparatus (D Hainburg, Germany) was used. Rotating basket (USP method I) was adopted for the dissolution study of all tablet formulations. For ketoprofen, the dissolution media used was 7.4 ph phosphate buffer. Temperature of dissolution medium was maintained at 37± 0.5 C and the rotating speed was 100 rpm. Samples of 5 ml were taken at time intervals of 0.5, 1, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, , 12.0, 18.0 and 24 h and filtered using filter paper of 0.45 µm. Then all samples were observed spectrophotometrically (UV visible spectrophotometer 1601, Shimadzu) and their respective absorbances were noted. Then, the percent release was calculated for all tablets from the standard curves. Drug release kinetics investigation The following kinetic models and equations were applied on the data obtained from in vitro dissolution studies of different matrix tablets formulations to determine the release kinetics (Table 2). Statistical analysis Statistical analysis were performed, using computer based excel program for calculation of mean and standard deviation.
3 Jan et al. 603 Table 1. Ketoprofen tablet formulation. D:P ratio Drug Polymer Filler (lactose) Lubricant Co-excipients 10:1 100 mg 200 mg Ketoprofen-polymer matrices PGA 0.5% PGA-co-CL PGA-co-PDL 10 mg 89 mg 1 mg Ethocel 100 FP 10:2 100 mg PGA PGA-co-CL PGA-co-PDL Ethocel 100 FP 20 mg 79 mg 1 mg :3 100 mg PGA PGA-co-CL PGA-co-PDL Ethocel 100 FP 30 mg 69 mg 1 mg Table 2. Kinetic models and equations applied on the data of in vitro dissolution studies. 1 Zero-order kinetics W = K 1t (Xu and Sunada, 1995) 2 First-order kinetics In (100-W) = In100 K 2t (Xu and Sunada, 1995) 3 Higuchi-kinetics W = K 4t 1/2 (Higuchi, 1963) 4 Hixson-Crowell kinetics (100 - W) 1/3 = 100 1/3 - K 3t (Xu and Sunada, 1995) 5 Korsmeyer-Peppas equation Mt/M = K 5 t n (Ritger and Peppas, 1987) RESULTS AND DISCUSSION Drug release studies Drug release studies were carried out on all formulations after the dissolution study conducted on each formulation. The release profile of ketoprofen tablets containing different types of polymers, that is, PGA, PGAco-caprolactone, PGA-co-pentadecalactone and Ethocel FP100 premium in different ratios of 10:1, 10:2 and 10:3, is given in Figures 1 to 3. Figure 4 shows comparison of conventional tablets of ketoprofen and reference SR tablets of Ketoprofen with the prepared ketoprofen matrix tablets with drug to polymer ratio of 10:2 of different polymers. From the Figures 1, 2 and 3, it can be observed that the prepared matrix formulations of ketoprofen showed reduced release profiles from that of the standard conventional tablets of the respective drugs. These figures also showed that the release profile is more decreased in case of the tablets containing FP premium grades of Ethocel 100 as compared to other polymers which have comparatively larger particles. It can be observed from these figures that those formulations containing three new polymers showed about 95 to 98% release of the drug from tablet in 24 h; whereas, in case of Ethocel FP100 premium it showed less release in 24 h. Swelling of the matrix tablets occurred during the dissolution. This may be due to hydrating property of the polymer which eventually leads to the swelling of the tablet. Due to this swelling phenomena, the polymer s glass transition temperature (Tg), the dissolution solvent provides a stress due which there is relaxation response in the polymer-chains and this create an increase in the distance between the polymer-chains (Khan and Zhu, 2001a). An increase in the molecular volume is produced in the hydrated polymer, due to which free volume is diminished because of the presence of microspores. This could be a shift in release mechanism of the drug from polymer. A lot of other researchers and investigators also observed the same results when they were performing their studies (Khan and Zhu, 2001). In vitro drug release kinetics Drug release kinetics for each matrix was analyzed using the modals discussed earlier. Tables 3, 4 and 5 show the release kinetics of ketoprofen tablets having different drug to polymer ratio of 10:1, 10:2 and 10:3. The n value
4 Percentage Release Percentage Release 604 Afr. J. Pharm. Pharmacol. 120 Release profile of Ketoprofen + Polymers (10:1) hr 0.5hr 1hr 1 1.5hr 2hr 2 3hr 3 4hr 4 5hr 5 6hr 6 8hr 8 10hr 12hr 16hr 24hr Time Elapsed Time Elapsed (h) Poly(glycolide).PGA PGA-co-Pentadecalactone PGA-co-Caprolactone Ethocel FP100 Premium Figure 1. Comparison of percent drug release from varying polymers at drug to polymer ratio 10: Release profile of Ketoprofen + Polymers (10:2) hr 0.5hr 1hr 1.5hr 2hr 3hr 4hr 5hr 6hr 8hr 10hr 12hr 16hr 24hr Time Elapsed Time Elapsed (h) Poly(glycolide).PGA PGA-co-Pentadecalactone PGA-co-Caprolactone Ethocel FP100 Premium Figure 2. Comparison of percent drug release from varying polymers at drug to polymer ratio 10:2. was also greater than 0.5. it indicates that the ketoprofen formulations shows anomalous-non Fickian drugdiffusion. These results confirming with the findings of Amit (2010), in whose investigation on zidovudine release from guar gum matrix tablets, shows a higher value of n, that is, n > 0.5. Here, the author (Amit) concluded that
5 Percentage Release Jan et al Release profile of Ketoprofen + Polymers (10:3) hr 0.5hr 1hr 1.5hr 2hr 3hr 4hr 5hr 6hr 8hr 10hr 12hr 16hr 24hr Time Elapsed Time Elapsed (h) Poly(glycolide).PGA PGA-co-Caprolactone PGA-co-Pentadecalactone Ethocel FP100 Premium Figure 3. Comparison of percent drug release from varying polymers at drug to polymer ratio 10:3. (h) Figure 4. Comparison of percent drug release from varying polymers at drug to polymer ratio 10:2 along with conventional dosage form and SR Tablet. mechanism of the drug release was a result of coupling of two mechanisms, that is, erosion and diffusion. The formulation containing Ethocel standard FP100 premium showed better release kinetics as compared to other formulations containing different grades of polymers.
6 606 Afr. J. Pharm. Pharmacol. Table 3. Release kinetics of controlled release tablets of Ketoprofen + PGA, PGA-co-CL, PGA-co-PDL and Ethocel FP100 at drug to polymer ratio (D:P) of 10:1 in ph 7.4 phosphate buffer. Formulation ketoprofen + polymers W = k1t (100-w) = ln100-k2t (100-w)1/3= 1001/3-k3t W = k4t1/2 Mt / M = k5 tn k1 ± S D r1 k2 ± SD r2 k3 ± SD r3 k4± SD r4 k5 ± SD r5 n Controlled release tablets of Ketoprofen - PGA 10: ± ± ± ± ± Controlled release tablets of Ketoprofen - PGA-co-CL 10: ± ± ± ± ± Controlled release tablets of Ketoprofen - PGA-co-PDL 10: ± ± ± ± ± Controlled release tablets of Ketoprofen - Ethocel FP100 Premium 10: ± ± ± ± ± Table 4. Release kinetics of controlled release tablets of Ketoprofen + PGA, PGA-co-CL, PGA-co-PDL and Ethocel FP100 at drug to polymer ratio (D:P) of 10:2 in ph 7.4 phosphate buffer. Formulation ketoprofen + polymers W = k 1t (100-w) = ln100-k 2t (100-w) 1/3 = 100 1/3 - k 3t W = k 4t 1/2 M t / M = k5 t n k1 ± S D r1 k2 ± SD r2 k3 ± SD r3 k4 ± SD r4 k5 ± SD r5 n Controlled release tablets of ketoprofen - PGA 10: ± ± ± ± ± Controlled release tablets of ketoprofen - PGA-co-CL 10: ± ± ± ± ± Controlled release tablets of ketoprofen - PGA-co-PDL 10:2 453 ± ± ± ± Controlled release tablets of ketoprofen - Ethocel FP100 Premium 10: ± ± ± ± ± Conclusion The results obtained from different parameters showed that polymers: polyglycolide, PGA-cocaprolactone, PGA-co-pentadecalactone and Ethocel FP100 Premium can be used successfully in order to develop directly compressed prolonged release tablets of slightly soluble drugs such as ketoprofen. Particle size of polymer is a determining factor in controlling the release of ketoprofen from tablets. Ethocel standard FP100 polymers extend the release rates of drug more efficiently then the conventional granular form of the other three polymers. Further, the three new polymers and Ethocel FP100 could efficiently extend the release of the drugs as compared to the reference conventional formulation. The new polymers, if
7 Jan et al. 607 Table 5. Release kinetics of controlled release tablets of Ketoprofen + PGA, PGA-co-CL, PGA-co-PDL and Ethocel FP100 at drug to polymer ratio (D:P) of 10:3 in ph 7.4 phosphate buffer. Formulation ketoprofen + polymers W = k1t (100 - w) = ln100 - k2t (100-w)1/3 = 1001/3 - k3t W = k4t1/2 Mt / M = k5 tn k1 ± S D r1 k2 ± SD r2 k3 ± SD r3 k4 ± SD r4 k5 ± SD r5 n Controlled release tablets of ketoprofen - PGA 10: ± ± ± ± ± Controlled release tablets of ketoprofen - PGA-co-CL 10: ± ± ± ± ± Controlled release tablets of ketoprofen - PGA-co-PDL 10: ± ± ± ± ± Controlled release tablets of ketoprofen - Ethocel FP100 Premium 10: ± ± ± ± ± made into fine particles will give more extended release which can be used as polymers of choice in CR formulations in the future. ACKNOWLEDGEMENTS The authors are thankful to Dr. Gillian A. Hutcheon and Dr. Elsie Gaskell, Senior Lecturers in School of Pharmacy and Chemistry, Liverpool John Moores University, Liverpool, UK, for providing me facilities for polymer synthesis. We are also thankful to the HEC Pakistan for providing me the training facility in Liverpool UK, for polymer synthesis. REFERENCES Amit SY (2010). Design and evaluation of Guar gum based controlled release matrix tablets of Zidovudine. J. Pharm. Sci. Technol., 2(3): Drug Delivery (2007). Available at: Evans JM, MacDonald TM (1996). Tolerability of topical NSAIDs in the elderly. Do they really convey a safety advantage? Drugs Ageing, 9: Green GA (2001). Understanding NSAIDs: from aspirin to COX-2. Clin. Corner Sports Med., 3: Higuchi T (1963). Mechanism of Rate of Sustained-Action Medication. Theoretical Analysis of Rate of Solid Drugs Dispersed In Matrices. J. Pharm. Sci., 52: Jan SU, Khan GM, Khan KA, Rehman A, Khan H (2011). Invitro release pattern of Ketoprofen using ethyl cellulose ether derivatives. J. Appl. Pharm., 01(03): Liversidge GG (1981). Ketoprofen. In Analytical Profiles of Drug Substances Volume 10, K. Florey (ed.), Academic Press, London, UK. pp Therapeutic Drugs (1991). Dollery C. Churchill Livingstone, London, UK, 2: Kantor TG (1986). Ketoprofen: a review of its pharmacologic and clinical properties. Pharmacotherapy, 6: Khan GM, Zhu JB (2001). Evaluation of Ethocel Premium ethylcellulose derivatives with different molecular weighs as controlled release matrix forming functional polymers for Ibuprofen. Sciences, 1: Ritger RL, Peppas NS (1987). A simple equation for disposition of solute release ll: Fickian and anomalous release from swellable devices. J. Control Release, 5: Vavra (1987). Ketoprofen. In Nonsteroidal Anti-Inflammatory Drugs, A. J. Lewis, D. E. First (eds.), Marcel Dekker Inc., New York, USA, pp Villegas I, La Casa C, de la, Lastra AA, Motilva V, Herrerías JM, Martin MJ (2004). Mucosal damage induced by preferential COX-1 and COX-2 inhibitors: role of prostaglandins and inflammatory response. Life Sci., 74: Wahab A, Khan GM, Akhlaq M, Khan NR, Hussain A, Zeb A, Rehman A, Shah KU (2011). Pre-formulation investigation and in vitro evaluation of directly compressed ibuprofen- Ethocel oral controlled release matrix tablets: A kinetic approach. Afr. J. Pharm. Pharm., 5(19): Xu GJ, Sunada H (1995). Influence of formulation changes on drug release kinetics from hydroxypropyl methylcellulose matrix tablets. Chem. Pharm. Bull., 43:
DESIGN AND EVALUATION OF DRUG RELEASE KINETICS OF MELOXICAM SUSTAINED RELEASE MATRIX TABLETS
Academic Sciences International Journal of Current Pharmaceutical Research ISSN- 0975-7066 Vol 4, Issue 1, 2012 Research Article DESIGN AND EVALUATION OF DRUG RELEASE KINETICS OF MELOXICAM SUSTAINED RELEASE
More informationFormulation and Evaluation of Effervescent Floating Tablet of Amlodipine besylate
Research J. Pharm. and Tech. 1(4): Oct.-Dec. 28, ISSN 974-3618 www.rjptonline.org RESEARCH ARTICLE Formulation and Evaluation of Effervescent Floating Tablet of Amlodipine besylate Pare A, Yadav SK and
More informationSPECTROPHOTOMETRIC ESTIMATION OF MELOXICAM IN BULK AND ITS PHARMACEUTICAL FORMULATIONS
SPECTROPHOTOMETRIC ESTIMATION OF MELOXICAM IN BULK AND ITS PHARMACEUTICAL FORMULATIONS B.DHANDAPANI, S.ESWARA MURALI, N. SUSRUTHA, RAMA SWETHA, S K. SONIA RANI, T. SARATH BABU, G.V. SEETHARAMANJANEYULU,
More informationDeptt of Pharma Science SGRR ITS Patel Nagar, Dehradun (UK)
METHOD DEVELOPMENT AND ITS VALIDATION FOR SIMULTANEOUS ESTIMATION OF ATORVASTATIN AND AMLODIPINE IN COMBINATION IN TABLET DOSAGE FORM BY UV SPECTROSCOPY, USING MULTI-COMPONENT MODE OF ANALYSIS V. Juyal
More informationSIMPLE U.V. SPECTROPHOTOMETRIC METHODS FOR THE ESTIMATION OF OFLOXACIN IN PHARMACEUTICAL FORMULATIONS
Int. J. Chem. Sci.: 8(2), 2010, 983-990 SIMPLE U.V. SPECTROPHOTOMETRIC METHODS FOR THE ESTIMATION OF OFLOXACIN IN PHARMACEUTICAL FORMULATIONS C. SOWMYA *, Y. PADMANABHA REDDY, J. RAVINDRA REDDY, M. SIVA
More informationResearch and Reviews: Journal of Pharmacy and Pharmaceutical Sciences
Research and Reviews: Journal of Pharmacy and Pharmaceutical Sciences Formulation and Evaluation of Matrix Tablets of Albendazole for Colon Site Specific Drug Delivery Prasanth VV 1, Jayaprakash R 2 *,
More informationDual retard tablets of amlodipine besylate and atenolol
10 Formulation, optimization and evaluation of dual retard tablet of amlodipine besylate and atenolol Hypertension, commonly referred to as high blood pressure, is a medical condition where the pressure
More informationShould you have any questions, please contact Edith Chang, Ph.D., Senior Scientific Liaison ( or
Amlodipine and Tablets Type of Posting Posting Date Targeted Official Date Notice of Intent to Revise 26 Oct 2018 To Be Determined, Revision Bulletin Expert Committee Chemical Medicines Monographs 2 In
More information8 Formulaton, evaluation and optimization of immediate release layer of amlodipine besylate
8 Formulaton, evaluation and optimization of immediate release layer of amlodipine besylate Amlodipine besylate is antihypertensine and also used in angina. Conventional tablets are requiring to be administered
More informationPO. Vasan, Gandhinagar District, Gujarat, India, 3 Dean at Faculty of Pharmacy, Dharmsinh Desai University, Nadiad, Gujarat, India.
International Journal of ChemTech Research CODEN (USA): IJCRGG ISSN : 0974-4290 Vol.6, No.5, pp 2615-2619, Aug-Sept 2014 Development and Validation of Simultaneous Estimation of Cefpodoxime proxetil and
More informationMeloxicam vs etodolac cox 2 inhibition
Meloxicam vs etodolac cox 2 inhibition The Borg System is 100 % Meloxicam vs etodolac cox 2 inhibition of GI. Aspirin inhibits plt aggregration via inhibition of platelet COX. Meloxicam least. Etodolac
More informationDevelopment and Validation of UV Spectrophotometric Area Under Curve (AUC) method for estimation of Pyrantel Pamoate in Bulk and Tablet Dosage Form
International Journal of Interdisciplinary and Multidisciplinary Studies (IJIMS), 2014, Vol 1, No.7, 70-76. 70 Available online at http://www.ijims.com ISSN: 2348 0343 Development and Validation of UV
More informationN.C. A and T List of Approved Analgesics 1 of 5
1 of 5 Note to user: This list of commonly used analgesics and sedatives is not all-inclusive. The absence of an agent does not necessarily mean it is unacceptable. For any questions, call the Clinical
More informationAMOXICILLIN AND CLAVULANIC ACID TABLETS Draft proposal for The International Pharmacopoeia (February 2018)
February 2018 Draft for comment 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 AMOXICILLIN AND CLAVULANIC ACID TABLETS Draft
More informationQuantification of Albendazole in Dewormer Formulations in the Kenyan market
Available online at www.pelagiaresearchlibrary.com Advances in Applied Science Research, 2011, 2 (2): 9-13 Quantification of Albendazole in Dewormer Formulations in the Kenyan market H.N. Wanyika*, P G
More informationDEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE SIMULTANEOUS ESTIMATION OF ALISKIREN AND AMLODIPINE IN TABLET DOSAGE FORM
Page288 Research Article Pharmaceutical Sciences DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE SIMULTANEOUS ESTIMATION OF ALISKIREN AND AMLODIPINE IN TABLET DOSAGE FORM Divya P, Aleti P, Venisetty
More informationMetacam 1.5 mg/ml oral suspension for dogs
Metacam 1.5 mg/ml oral suspension for dogs Species:Dogs Therapeutic indication:pharmaceuticals: Neurological preparations: Analgesics, Other NSAIDs, Locomotor (including navicular and osteoarthritis) Active
More informationJust where it s needed.
Relief. Just where it s needed. Tissue-selective 7,8 Strong safety profile 5,6,10,11 For dogs and cats Onsior is available in a range of convenient and easy-to-dose formulations. Injectable solution for
More informationCompliance. Should you have any questions, please contact Praveen Pabba, Ph.D., ( or
Doxycycline Hyclate Delayed-Release Tablets Type of Posting Revision Bulletin Posting Date 28 Jul 2017 Official Date 01 Aug 2017 Expert Committee Chemical Medicines Monographs 1 Reason for Revision Compliance
More informationMATERIAL SAFETY DATA SHEET
MATERIAL SAFETY DATA SHEET SECTION 1 - CHEMICAL PRODUCT & COMPANY IDENTIFICATION Animal Health Group 812 Springdale Drive Exton, PA 19341 Emergency telephone Hours of operation Telephone 1-800-228-5635
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Rycarfa 100 mg tablets for dogs (BE, DE, ES, FR, IE, IT, NL, PT, UK) Rycarfa vet 100 mg tablets for dogs (DK, FI) Carprox
More informationKamepalli Sujana et al. / Journal of Pharmacy Research 2014,8(12), Available online through
Research Article ISSN: 0974-6943 Available online through www.jpronline.info Simultaneous equation method for the estimation of Atorvastatin calcium and Amlodipine besylate in bulk and in combined tablet
More informationAmlodipine, Valsartan, and Hydrochlorothiazide Tablets
. Table Interim Revision Announcement Official November 1, 2017 Amlodipine 1 Amlodipine, Valsartan, and Hydrochlorothiazide Tablets 2 (Continued) Tablet Strength Nominal Amlodipine/ Nominal Concentra-
More informationJournal of Applied Pharmaceutical Research ISSN No
SIMULTANEOUS ESTIMATION OF PYRANTEL PAMOATE, PRAZIQUANTEL & FEBANTEL BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY USING DUAL WAVELENGTH Rupali Sajjanwar (Rupali Jitendra Paranjape)*, Shyamala Bhaskaran, Kulesh
More informationTamboli Ashpak Mubarak et al. IRJP 2 (8)
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN 2230 8407 Available online http://www.irjponline.com Research Article DEVELOPMENT AND VALIDATION OF STABILITY INDICATING HPLC METHOD FOR SIMULTANEOUS DETERMINATION
More informationFORMULATION AND EVALUATION OF S-(-)-AMLODIPINE BESYLATE AND NEBIVOLOL HYDROCHLORIDE TABLETS
Digest Journal of Nanomaterials and Biostructures Vol. 5, No 1, March 2010, p. 201 205 FORMULATION AND EVALUATION OF S-(-)-AMLODIPINE BESYLATE AND NEBIVOLOL HYDROCHLORIDE TABLETS S. A. SHAIKH *, S. S.
More informationVALIDATED RP-HPLC METHOD FOR THE SIMULTANEOUS DETERMINATION OF AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM IN BULK AND PHARMACEUTICAL FORMULATION
INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY Available online at www.ijrpc.com Research Article VALIDATED RP-HPLC METHOD FOR THE SIMULTANEOUS DETERMINATION OF AMLODIPINE BESYLATE AND ATORVASTATIN
More informationMeloxicam withdrawal time veterinarian bovine
Meloxicam withdrawal time veterinarian bovine The Borg System is 100 % Meloxicam withdrawal time veterinarian bovine Meloxicam Pain Relief in Cows and Calves. Meloxicam meat and milk withdrawal the standard
More informationNon-steroidal anti-inflammatory drugs (NSAIDs) are used widely to relieve pain, with or without
May 2013 Contents About NSAIDs What about COXselectivity? How effective are NSAIDs? Adverse effects of NSAIDs How frequent are the adverse effects of NSAIDs? General prescribing guidelines for NSAIDs What
More informationSpectrophotometric Method for Simultaneous Estimation of Amlodipine Besylate in Pharmaceutical Formulation
Spectrophotometric Method for Simultaneous Estimation of Amlodipine Besylate in Pharmaceutical Formulation Naresh Kalra*, Suresh Choudhary Department of Pharmaceutical sciences, Alwar Pharmacy College,
More informationInternational Journal of Pharmaceutical Research & Analysis
13 International Journal of Pharmaceutical Research & Analysis e-issn: 2249 7781 Print ISSN: 2249 779X www.ijpra.com RP-HPLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF AMLODIPINE
More informationDouble-Layered Mucoadhesive Tablets Containing Nystatin
Double-Layered Mucoadhesive Tablets Containing Nystatin Submitted: March 11, 2002; Accepted: July 24, 2002 Juan Manuel Llabot 1, Ruben Hilario Manzo 1 and Daniel Alberto Allemandi 1 1 Departamento de Farmacia,
More informationFORMULATION AND EVALUATION OF TOPICAL GEL OF MELOXICAM
INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY Available online at www.ijrpc.com Research Article FORMULATION AND EVALUATION OF TOPICAL GEL OF MELOXICAM Loveleenpreet kaur 1* and Prabhjot
More informationInternational Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access.
I J A P B International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access. ISSN: 2454-8375 COMPARISON OF ANTIMICROBIAL ACTIVITY AND MIC OF BRANDED
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Animeloxan 1.5 mg/ml oral suspension for dogs. Active substance: Meloxicam 1.5 mg (equivalent to 0.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Animeloxan 1.5 mg/ml oral suspension for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of suspension contains:
More informationSimultaneous UV-spectrophotometric estimation of ibuprofen and moxifloxacin in ph 6.8 phosphate buffer
IJPAR Vol.4 Issue 2 April-June-2015 Journal Home page: ISSN: 2320-2831 Research article Open Access Simultaneous UV-spectrophotometric estimation of ibuprofen and moxifloxacin in ph 6.8 phosphate buffer
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT DINALGEN 60 mg/ml solution for injection for pigs (all countries except FI and SE) DINALGEN VET 60 mg/ml solution for injection
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Zubrin 50 mg oral lyophilisates for dogs Zubrin 100 mg oral lyophilisates for dogs Zubrin 200 mg oral lyophilisates
More informationJournal of Global Trends in Pharmaceutical Sciences
An Elsevier Indexed Journal ISSN-2230-7346 Journal of Global Trends in Pharmaceutical Sciences A NEW IMPROVED RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE AND
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION 1. SUMMARY OF THE DOSSIER Rheumocam is a generic medicinal product as defined in Article 13(2) (b) of Directive 2001/82/EC, as amended by Directive 2004/28/EC. The reference veterinary
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT AT, BE, BG, CY, CZ, DE, EE, EL, ES, FR, HR, HU, IE, IT, LT, LU, NL, PT, RO, SK, UK: Kelaprofen 100 mg/ml, solution for injection
More informationDETERMINATION OF ACTIVE SUBSTANCES IN MULTICOMPONENT VETERINARY PREPARATIONS OF ANTIPARASITIC ACTION BY HPLC METHOD
Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 67 No. 5 pp. 463ñ468, 2010 ISSN 0001-6837 Polish Pharmaceutical Society DETERMINATION OF ACTIVE SUBSTANCES IN MULTICOMPONENT VETERINARY PREPARATIONS OF
More informationCommonly Used Analgesics
Commonly Used Analgesics The following analgesics are intended for general use in the species of laboratory animals commonly used at NEOUCOM. The animals genetic background and other factors may have a
More informationSZENT ISTVÁN UNIVERSITY. Doctoral School of Veterinary Science
SZENT ISTVÁN UNIVERSITY Doctoral School of Veterinary Science Comparative pharmacokinetics of the amoxicillinclavulanic acid combination in broiler chickens and turkeys, susceptibility and stability tests
More informationINTERNATIONAL RESEARCH JOURNAL OF PHARMACY
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Research Article FORMULATION AND EVALUATION OF FAST DISSOLVING TABLETS OF OFLOXACIN BY DIRECT COMPRESSION METHOD Shivaramakrishna
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NEFOTEK 100 mg/ml solution for injection for cattle, horses and pigs [AT, CZ, IE, PL, SK, UK, DE, FR, ES, HU, IT, SI] COXOFEN
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Carprodyl Quadri 120 mg chewable tablets for dogs Carprodyl vet. 120 mg chewable tablets for dogs (FI, SE, DK) 2. QUALITATIVE
More informationDevelopment and validation of a HPLC analytical assay method for amlodipine besylate tablets: A Potent Ca +2 channel blocker
Development and validation of a HPLC analytical assay method for amlodipine besylate tablets: A Potent Ca +2 channel blocker Richa Sah* and Saahil Arora 1. ISF College of Pharmacy, Moga, Punjab, India
More informationSpecific and Simple HPLC Assay of Ecofriendly Meloxicam in Pharmaceutical Formulations K.T. Mahmood 1, B.Khan 2, M. Ashraf 3 and I. U.
Specific and Simple HPLC Assay of Ecofriendly Meloxicam in Pharmaceutical Formulations K.T. Mahmood 1, B.Khan 2, M. Ashraf 3 and I. U.Haq 4 1 DTL,Health Department Punjab, Lahore, 2 Lahore College for
More informationInternational Journal of Drug Delivery 4 (2012) Original Research Article
International Journal of Drug Delivery 4 (2012) 366-374 http://www.arjournals.org/index.php/ijdd/index Original Research Article ISSN: 0975-0215 Control the drug release of Levofloxacin by using different
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/MRL/728/00-FINAL April 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS STREPTOMYCIN AND
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT WONDERCEF powder and solvent for solution for injection for horses not intended for the production of foods for human consumption.
More informationENHANCEMENT OF DISSOLUTION AND ANTI INFLAMMATORY EFFECT OF MELOXICAM USING SOLID DISPERSIONS
International Journal of Applied Pharmaceutics Vol 2 Issue 1, 2 Research Article ENHANCEMENT OF DISSOLUTION AND ANTI INFLAMMATORY EFFECT OF MELOXICAM USING SOLID DISPERSIONS MOHAMMED JAFAR 1*, DEHGHAN
More informationDetermination of ofloxacin in bulk drug and pharmaceutical dosage form by high performance liquid chromatography method
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2015, 7 (10):188-192 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationINTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE
RESEARCH ARTICLE INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE A Path for Horizing Your Innovative Work METHOD DEVLOPMENT AND VALIDATION OF CEFIXIME AND MOXIFLOXACIN IN PHARMACEUTICAL
More informationEPAR type II variation for Metacam
23 June 2011 EMA/674662/2011 International Non-proprietary Name: Meloxicam Procedure No. EMEA/V/C/033/II/084 EU/2/97/004/026, 33-34 Scope: Type II Addition of indication for cats Page 1/6 Table of contents
More informationIsocratic Reverse Phase High Performance Liquid Chromatographic Estimation of Ramipril and Amlodipine in Pharmaceutical Dosage Form
Isocratic Reverse Phase High Performance Liquid Chromatographic Estimation of Ramipril and Amlodipine in Pharmaceutical Dosage Form Manikanta Kumar. A, P. Vijay Kumar *, Mahesh Nasare, Venkateswar Rao,
More informationVol-3, Issue-4, Suppl-2, Nov 2012 ISSN: Bandi et al PHARMA SCIENCE MONITOR
PHARMA SCIENCE MONITOR AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES PREPARATION AND CHARACTERIZATION OF NANOPARTICLES FOR DISSOLUTION RATE ENHANCEMENT OF MELOXICAM Bandi Ramesh*, S Parthiban, S
More informationPradhan Prasanna Kumar et al. Int. Res. J. Pharm. 2014, 5 (9) INTERNATIONAL RESEARCH JOURNAL OF PHARMACY
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Research Article ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF FENAC SODIUM AND FLOXACIN IN THEIR
More informationformulations, in dissolution studies. The method is rapid, simple, accurate, and precise without the need of high-cost investment.
International Journal of Pharmacy and Pharmaceutical Sciences ISSN- 0975-1491 Vol 8, Issue 2, 2016 Original Article SIMULTANEOUS DETERMINATION OF KETOPROFEN AND ACETAMINOPHEN IN FIXED-DOSE COMBINATION
More informationScholars Research Library
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 200, 2 (2): 47-478 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-507 USA CODEN: DPLEB4
More informationOral and intestinal candidiasis. As adjuvant treatment with other local nystatin preparations to prevent reinfection.
1. NAME OF THE MEDICINAL PRODUCT Nystatin Orifarm, 100 000 IU/ml oral suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 100 000 IU nystatin. Excipients with known effect: - Methyl parahydroxybenzoate
More informationUltra-Fast Analysis of Contaminant Residue from Propolis by LC/MS/MS Using SPE
Ultra-Fast Analysis of Contaminant Residue from Propolis by LC/MS/MS Using SPE Matthew Trass, Philip J. Koerner and Jeff Layne Phenomenex, Inc., 411 Madrid Ave.,Torrance, CA 90501 USA PO88780811_L_2 Introduction
More informationSUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationUnited Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS MUTUAL RECOGNITION PROCEDURE
United Kingdom Veterinary Medicines Directorate Woodham Lane New Haw Addlestone Surrey KT15 3LS MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT Clavudale
More informationINTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES
International Standard Serial Number (ISSN): 2249-687 International Journal of Institutional Pharmacy and Life Sciences 5(2): March-April 215 INTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE
European Medicines Agency Veterinary Medicines and Inspections EMEA/CVMP/211249/2005-FINAL July 2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE DIHYDROSTREPTOMYCIN (Extrapolation to all ruminants)
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Rifen 100 mg/ml solution for injection for horses, cattle and swine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains:
More informationProcedure # IBT IACUC Approval: December 11, 2017
IACUC Procedure: Anesthetics and Analgesics Procedure # IBT-222.04 IACUC Approval: December 11, 2017 Purpose: The purpose is to define the anesthetics and analgesics that may be used in mice and rats.
More informationScientific discussion
21 February 2011 EMA/CVMP/510016/2010 Veterinary Medicines and Product Data Management This module reflects the initial scientific discussion for the approval of Melosus (as published in February 2011).
More informationNSAID Toxicity in Dogs & Cats Beware of Ibuprofen!
NSAID Toxicity in Dogs & Cats Beware of Ibuprofen! One of the most common drug toxicities in companion animal medicine is accidental ingestion of over-the-counter non-steroid anti-inflammatory (NSAID)
More informationDetermination of Amlodipine in Rat Plasma by UV Spectroscopy
Determination of Amlodipine in Rat Plasma by UV Spectroscopy P. Srinivasulu 1*, B.K. Gowthami 2, T.N.V. Ganesh Kumar 1, D. Surya Narayana Raju 1, S. Vidyadhara 1 1 Chebrolu Hanumaiah Institute of Pharmaceutical
More informationVeterinary Medicinal Product
Veterinary Medicinal Product Carprodyl Quadri 120 mg chewable tablets for dogs PART I B Pharmaceutical Form Chewable tablet Veterinary Medicinal Product Carprodyl Quadri 120mg chewable tablets for dogs
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Melosolute 20 mg/ml solution for injection for cattle, pigs and horses. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains:
More informationABSTRACT. Usharani N, Divya K and Ashrtiha VVS. Original Article
Original Article Development and Validation of UV-Derivative Spectroscopic and RP-HPLC Methods for the Determination of Amlodipine Besylate and Valsartan in Tablet Dosage form and Comparison of the Developed
More informationFinal Report. Project code: P.PSH.0653 Prepared by: Fiona Cotter Troy Laboratories Pty Ltd Date published: July 2014
Final Report Project code: P.PSH.0653 Prepared by: Fiona Cotter Troy Laboratories Pty Ltd Date published: July 2014 PUBLISHED BY Meat & Livestock Australia Limited Locked Bag 991 NORTH SYDNEY NSW 2059
More informationOral and intestinal candidiasis. As adjuvant treatment with other local nystatin preparations to prevent reinfection.
1. NAME OF THE MEDICINAL PRODUCT Nystimex, 100 000 IU/ml oral suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains 100 000 IU nystatin. Excipients: Methyl parahydroxybenzoate 1 mg Sodium
More informationMOXIFLOXACIN HYDROCHLORIDE (MOXIFLOXACINI HYDROCHLORIDUM) Draft proposal for The International Pharmacopoeia. (January 2018)
January 2018 DRAFT FOR COMMENT 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 MOXIFLOXACIN HYDROCHLORIDE (MOXIFLOXACINI HYDROCHLORIDUM) Draft proposal
More informationDevelopment and Validation of Amlodipine Impurities in Amlodipine Tablets Using Design Space Computer Modeling
American Journal of Analytical Chemistry, 2016, 7, 918-926 http://www.scirp.org/journal/ajac ISSN Online: 2156-8278 ISSN Print: 2156-8251 Development and Validation of Amlodipine Impurities in Amlodipine
More informationPharma Research Library. 2013, Vol. 1(1):19-29
Available online at www.pharmaresearchlibrary.com Pharma Research Library International Journal of Current Trends in Pharmaceutical Research 2013, Vol. 1(1):19-29 Pharma Research Library Method development
More informationMoxifloxacin (as hydrochloride) 400 mg Tablets WHOPAR part 6 November 2017 (Hetero Labs Limited), TB 315
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationProviding Constant Analgesia with OROS Ò Hydromorphone
Vol. 33 No. 2S February 2007 Journal of Pain and Symptom Management S19 Advances in the Long-Term Management of Chronic Pain: Recent Evidence with OROS Ò Hydromorphone, a Novel, Once-Daily, Long-Acting
More informationISMP Canada HYDROmorphone Knowledge Assessment Survey
ISMP Canada HYDROmorphone Knowledge Assessment Survey Knowledge Assessment Questions 1. In an equipotent dose, HYDROmorphone is more potent than morphine. True False Unsure 2. HYDROmorphone can be given
More informationC 22 H 28 FNa 2 O 8 Pıı516.4
SIMULTANEOUS DETERMINATION OF DEXAMETHASONE SODIUM PHOSPHATE AND CHLORAMPHENICOL IN OPHTHALMIC SOLUTIONS W.A. Shadoul, E.A. Gad Kariem, M.E. Adam, K.E.E. Ibrahim* Department of Pharmaceutical Chemistry,
More informationMETHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF OFLOXACIN AND ORNIDAZOLE IN TABLET DOSAGE FORM BY RP-HPLC
METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF OFLOXACIN AND ORNIDAZOLE IN TABLET DOSAGE FORM BY RP-HPLC B.Dhandapani *1, N.Thirumoorthy 2, Shaik Harun Rasheed 3, M.Rama kotaiah 3
More informationPROPYLENE GLYCOL FREE MINOXIDIL TOPICAL FORMULATION FOR HAIR LOSS BASED ON PATENTED TECHNOLOGY
Page 1 of 7 LICENSING OPPORTUNITY PROPYLENE GLYCOL FREE MINOXIDIL TOPICAL FORMULATION FOR HAIR LOSS BASED ON PATENTED TECHNOLOGY NO PROPYLENE GLYCOL NO SCALP IRRITATION, NO GREASY HAIR BIOEQUIVALENT ABSORPTION
More informationApplication of hydrotropic solubilization technique for simultaneous estimation and validation of ofloxacin and ornidazole in tablet dosage form
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2015, 7 (11):234-240 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4
More informationDEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF AMLODIPINE BESYLATE AND IRBESARTAN
Indexed in Cite Factor - Directory of International Research Journals in association with leading Universities DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF AMLODIPINE BESYLATE
More informationFor the treatment and prevention of infections caused by:
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CYDECTIN 0.1 % W/V ORAL SOLUTION for sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains Active substance Moxidectin
More informationAvailable online International Journal of Pharmaceutical Research & Allied Sciences, 2016, 5(4):37-44.
Available online www.ijpras.com International Journal of Pharmaceutical Research & Allied Sciences, 2016, 5(4):37-44 Research Article ISSN : 2277-3657 CODEN(USA) : IJPRPM DEVELOPMENT AND VALIDATION OF
More informationFormulation, Development & Characterization of Ofloxacin Microspheres
Formulation, Development & Characterization of Ofloxacin Microspheres Vidhyaa Kumari a, Vignesh Muruganandham b* a School of Pharmacy & Applied Science, La Trobe University, Bendigo, Victoria 3552, Australia
More informationUsing of polydiallyldimethylammonium chloride for removal Cryptosporidium from the public recreational water venue
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2014, 6(6):39-43 Research Article ISSN : 0975-7384 CODEN(USA) : JCPRC5 Using of polydiallyldimethylammonium chloride for
More informationMeloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration
Inflamm. res. 50, Supplement 1 (2001) S5 S9 1023-3830/01/01S5-05 $ 1.50+0.20/0 Birkhäuser Verlag, Basel, 2001 Inflammation Research Meloxicam: a review of its pharmacokinetics, efficacy and tolerability
More informationStart of new generation of NSAIDs?
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Start of new generation of NSAIDs? Author : Peter Lees Categories : Vets Date : May 16, 2011 Peter Lees discusses development
More informationDevelopment of Analytical Methods for the Determination of Flunixin and Phenylbutazone Drug Residues in Edible Bovine Tissues
Development of Analytical Methods for the Determination of Flunixin and Phenylbutazone Drug Residues in Edible Bovine Tissues Philip Asea, John Patterson, & Joe Boison CVDR, Health of Animals Laboratory,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT RONAXAN 20mg Tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Active substance : Doxycycline (as doxycycline
More informationNew Zealand Consumer Medicine Information
New Zealand Consumer Medicine Information FLUCLOXACILLIN Flucloxacillin (as the sodium salt) 250 mg and 500 mg capsules Flucloxacillin (as the sodium salt) 125 mg/5 ml and 250 mg/5 ml powder for oral solution
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Melosolute 5 mg/ml solution for injection for cattle, pigs, dogs and cats. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml
More informationPrescription Label. Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long):
Prescription Label Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long): Prescribing Veterinarian's Name & Contact Information: Refills: [Content to be provided
More informationUSA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION
VIRBAC CORPORATION USA Product Label http://www.vetdepot.com P.O. BOX 162059, FORT WORTH, TX, 76161 Telephone: 817-831-5030 Order Desk: 800-338-3659 Fax: 817-831-8327 Website: www.virbacvet.com CLINTABS
More information